Open Payments

Massachusetts Eye And Ear Infirmary

Type
Teaching hospital
Where
Boston, MA
Medicare CCN
220075
Received
$2,147,592 in 169 records, 2025 ($1,382,531 general, $765,060 research)
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2025General payment45$1,382,531
2025Research payment124$765,060

By company

CompanyRecordsAmountYears
Bausch & Lomb Americas Inc.5$635,4392025
Regeneron Pharmaceuticals, Inc.12$515,0492025
Janssen Research & Development, LLC28$337,3632025
Sumitomo Pharma America, Inc.36$136,9292025
Analog Devices Inc.1$116,0732025
KARL STORZ Endoscopy-America14$98,9052025
Cochlear Americas10$65,6232025
Spark Therapeutics, Inc.3$44,2512025
KYOWA KIRIN, INC.33$41,9422025
Inspire Medical Systems, Inc.1$35,5282025
Genentech, Inc.1$20,0002025
Carl Zeiss Meditec, Inc.2$16,9352025
Philips North America LLC1$14,0002025
Astellas Pharma US Inc1$10,0002025
Advanced Bionics, LLC1$10,0002025
ABBVIE INC.4$9,6812025
Stryker Corporation3$9,3002025
Glaukos Corporation2$6,5182025
Sumitomo Pharma Co., Ltd.1$5,8542025
AERIN MEDICAL INC.1$5,0002025
Heidelberg Engineering, Inc.1$3,0002025
iotaMotion, Inc.1$3,0002025
Alcon Vision LLC1$2,5002025
3NT Medical1$2,0002025
Amgen Inc.1$1,3312025
Gyrus ACMI, Inc.3$1,2072025
Grace Medical, Inc.1$1572025

By nature of payment

NatureRecordsAmount
Research payment124$765,060
Royalty or License8$626,804
Grant12$495,735
Compensation for services other than consulting, including serving as faculty or as a speaker at a v2$126,073
Education12$96,905
Space rental or facility fees (teaching hospital only)4$28,500
Long term medical supply or device loan1$5,000
Charitable Contribution1$2,500
Debt forgiveness5$1,013

Records

DateCompanyAmountNatureFormProductStudyYear
2025-12-31KARL STORZ Endoscopy-America$21,670EducationIn-kind items and servicesIMAGE 1 Device, VIDEOIMAGING2025
2025-12-31KARL STORZ Endoscopy-America$19,266EducationIn-kind items and servicesIMAGE1 / COVIEW / IMAGE 1 S Device, MICRO/NOTES/MILITARY2025
2025-12-31KARL STORZ Endoscopy-America$13,776EducationIn-kind items and servicesIMAGE1 S CONNECT Device, VIDEOIMAGING2025
2025-12-31KARL STORZ Endoscopy-America$12,591EducationIn-kind items and servicesIMAGE1 S CONNECT Device, VIDEOIMAGING2025
2025-12-31KARL STORZ Endoscopy-America$11,335EducationIn-kind items and services2025
2025-12-31KARL STORZ Endoscopy-America$8,834EducationIn-kind items and servicesIMAGE1 H3-LINK Device, VIDEOIMAGING2025
2025-12-31KARL STORZ Endoscopy-America$7,843EducationIn-kind items and servicesNA Device, VIDEOIMAGING2025
2025-12-31KARL STORZ Endoscopy-America$621EducationIn-kind items and services2025
2025-12-31KARL STORZ Endoscopy-America$380EducationIn-kind items and servicesn.a. Device, VIDEOIMAGING2025
2025-12-31KARL STORZ Endoscopy-America$268EducationIn-kind items and services2025
2025-12-31KARL STORZ Endoscopy-America$182EducationIn-kind items and servicesn.a. Device, OR12025
2025-12-31KARL STORZ Endoscopy-America$134EducationIn-kind items and services2025
2025-12-22Analog Devices Inc.$116,073Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2025
2025-12-15Janssen Research & Development, LLC$72,312Research paymentCash or cash equivalentAn Open-label, Multicenter, Phase 2 Follow-on Study for Second Eye Treatment of Patients Previously Treated With a Recom2025
2025-12-11Janssen Research & Development, LLC$5,552Research paymentCash or cash equivalentFollow-up Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gen2025
2025-11-26KYOWA KIRIN, INC.$1,750Research paymentCash or cash equivalentA PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A 2025
2025-11-26KYOWA KIRIN, INC.$750Research paymentCash or cash equivalentA PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A 2025
2025-11-21Regeneron Pharmaceuticals, Inc.$435,500GrantCash or cash equivalent2025
2025-11-19ABBVIE INC.$2,190Research paymentCash or cash equivalentLong-term Follow-Up Study of RGX-314 and Fellow Eye Substudy (RGX-314 SRLTFU)2025
2025-11-14Bausch & Lomb Americas Inc.$179,065Royalty or LicenseCash or cash equivalentVISUDYNE Drug, Ophthalmology2025
2025-11-13Janssen Research & Development, LLC$4,764Research paymentCash or cash equivalentFollow-up Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gen2025
2025-11-03Sumitomo Pharma America, Inc.$2,849Research paymentCash or cash equivalentA PROSPECTIVE, OBSERVATIONAL STUDY IN ADULTS WITH RETINITIS PIGMENTOSA (RP)2025
2025-11-03Sumitomo Pharma America, Inc.$2,849Research paymentCash or cash equivalentA PROSPECTIVE, OBSERVATIONAL STUDY IN ADULTS WITH RETINITIS PIGMENTOSA (RP)2025
2025-11-03Sumitomo Pharma America, Inc.$2,849Research paymentCash or cash equivalentA PROSPECTIVE, OBSERVATIONAL STUDY IN ADULTS WITH RETINITIS PIGMENTOSA (RP)2025
2025-11-03Sumitomo Pharma America, Inc.$2,849Research paymentCash or cash equivalentA PROSPECTIVE, OBSERVATIONAL STUDY IN ADULTS WITH RETINITIS PIGMENTOSA (RP)2025
2025-11-03Sumitomo Pharma America, Inc.$2,849Research paymentCash or cash equivalentA PROSPECTIVE, OBSERVATIONAL STUDY IN ADULTS WITH RETINITIS PIGMENTOSA (RP)2025
2025-10-27Janssen Research & Development, LLC$7,637Research paymentCash or cash equivalentAn Open-label, Multicenter, Phase 2 Follow-on Study for Second Eye Treatment of Patients Previously Treated With a Recom2025
2025-10-20Sumitomo Pharma America, Inc.$16,500Research paymentCash or cash equivalentA PROSPECTIVE, OPEN-LABEL, SINGLE-ARM, DOSE-ESCALATION STUDY OF THE SAFETY AND TOLERABILITY OF A SINGLE SUBRETINAL UNIOC2025
2025-10-20Sumitomo Pharma America, Inc.$6,500Research paymentCash or cash equivalentA PROSPECTIVE, OPEN-LABEL, SINGLE-ARM, DOSE-ESCALATION STUDY OF THE SAFETY AND TOLERABILITY OF A SINGLE SUBRETINAL UNIOC2025
2025-10-20Sumitomo Pharma America, Inc.$3,500Research paymentCash or cash equivalentA PROSPECTIVE, OPEN-LABEL, SINGLE-ARM, DOSE-ESCALATION STUDY OF THE SAFETY AND TOLERABILITY OF A SINGLE SUBRETINAL UNIOC2025
2025-10-20Sumitomo Pharma America, Inc.$3,000Research paymentCash or cash equivalentA PROSPECTIVE, OPEN-LABEL, SINGLE-ARM, DOSE-ESCALATION STUDY OF THE SAFETY AND TOLERABILITY OF A SINGLE SUBRETINAL UNIOC2025
2025-10-20Sumitomo Pharma America, Inc.$2,088Research paymentCash or cash equivalentA PROSPECTIVE, OPEN-LABEL, SINGLE-ARM, DOSE-ESCALATION STUDY OF THE SAFETY AND TOLERABILITY OF A SINGLE SUBRETINAL UNIOC2025
2025-10-20Sumitomo Pharma America, Inc.$1,254Research paymentCash or cash equivalentA PROSPECTIVE, OPEN-LABEL, SINGLE-ARM, DOSE-ESCALATION STUDY OF THE SAFETY AND TOLERABILITY OF A SINGLE SUBRETINAL UNIOC2025
2025-10-15Janssen Research & Development, LLC$12,689Research paymentCash or cash equivalentFollow-up Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gen2025
2025-10-15Gyrus ACMI, Inc.$67Royalty or LicenseCash or cash equivalentGYRUS ACMI Device, Ear, Nose, Throat2025
2025-10-02Sumitomo Pharma America, Inc.$2,849Research paymentCash or cash equivalentA PROSPECTIVE, OBSERVATIONAL STUDY IN ADULTS WITH RETINITIS PIGMENTOSA (RP)2025
2025-10-01ABBVIE INC.$2,911Research paymentCash or cash equivalentLong-term Follow-Up Study of RGX-314 and Fellow Eye Substudy (RGX-314 SRLTFU)2025
2025-09-24Regeneron Pharmaceuticals, Inc.$11,500Research paymentCash or cash equivalentVEOPOZ Biological, OPTHALMOLOGY, NEUROLOGY, HEMATOLOGYA Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of 2025
2025-09-24Regeneron Pharmaceuticals, Inc.$6,500Research paymentCash or cash equivalentVEOPOZ Biological, OPTHALMOLOGY, NEUROLOGY, HEMATOLOGYA Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of 2025
2025-09-24Regeneron Pharmaceuticals, Inc.$2,062Research paymentCash or cash equivalentVEOPOZ Biological, OPTHALMOLOGY, NEUROLOGY, HEMATOLOGYA Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of 2025
2025-09-24Regeneron Pharmaceuticals, Inc.$1,500Research paymentCash or cash equivalentVEOPOZ Biological, OPTHALMOLOGY, NEUROLOGY, HEMATOLOGYA Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of 2025
2025-09-24Regeneron Pharmaceuticals, Inc.$623Research paymentCash or cash equivalentVEOPOZ Biological, OPTHALMOLOGY, NEUROLOGY, HEMATOLOGYA Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of 2025
2025-09-18Janssen Research & Development, LLC$5,465Research paymentCash or cash equivalentFollow-up Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gen2025
2025-09-16Regeneron Pharmaceuticals, Inc.$1,000Research paymentCash or cash equivalentEYLEA HD Biological, OPHTHALMOLOGYCost Analysis of Aflibercept 8 mg for Diabetic Macular Edema2025
2025-09-09KARL STORZ Endoscopy-America$1,000GrantCash or cash equivalent2025
2025-09-03Sumitomo Pharma America, Inc.$2,849Research paymentCash or cash equivalentA PROSPECTIVE, OBSERVATIONAL STUDY IN ADULTS WITH RETINITIS PIGMENTOSA (RP)2025
2025-09-03Sumitomo Pharma America, Inc.$1,686Research paymentCash or cash equivalentA PROSPECTIVE, OBSERVATIONAL STUDY IN ADULTS WITH RETINITIS PIGMENTOSA (RP)2025
2025-09-03Sumitomo Pharma America, Inc.$350Research paymentCash or cash equivalentA PROSPECTIVE, OBSERVATIONAL STUDY IN ADULTS WITH RETINITIS PIGMENTOSA (RP)2025
2025-09-01Janssen Research & Development, LLC$10,000Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2025
2025-08-27ABBVIE INC.$3,730Research paymentCash or cash equivalentLong-term Follow-Up Study of RGX-314 and Fellow Eye Substudy2025
2025-08-27Janssen Research & Development, LLC$2,800Research paymentCash or cash equivalentFollow-up Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gen2025
2025-08-21Regeneron Pharmaceuticals, Inc.$5,121Research paymentCash or cash equivalentEYLEA HD Biological, OPHTHALMOLOGYDisparities in follow up after diabetic retinopathy screening2025
2025-08-14Bausch & Lomb Americas Inc.$144,591Royalty or LicenseCash or cash equivalentVISUDYNE Drug, Ophthalmology2025
2025-08-14Cochlear Americas$1,158Research paymentIn-kind items and servicesMeasures sensitive to the presence of auditory nerve peripheral processes in patients with and without DFNA9 mutations2025
2025-08-06Janssen Research & Development, LLC$27,706Research paymentCash or cash equivalentFollow-up Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gen2025
2025-08-06Janssen Research & Development, LLC$10,229Research paymentCash or cash equivalentFollow-up Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gen2025
2025-07-31Alcon Vision LLC$2,500Space rental or facility fees (teaching hospital only)Cash or cash equivalent2025
2025-07-25Inspire Medical Systems, Inc.$35,528Research paymentCash or cash equivalentINSPIRE Device, NEUROLOGYCOMBO- Nerve Stimulation2025
2025-07-25ABBVIE INC.$850Research paymentCash or cash equivalentLong-term Follow-Up Study of RGX-314 and Fellow Eye Substudy2025
2025-07-25Grace Medical, Inc.$157Royalty or License (2 payments)Cash or cash equivalentOTOSHIELD PROTECTIVE BARRIER DRAPE Medical Supply, OTOLOGY2025
2025-07-22Cochlear Americas$46Debt forgivenessCash or cash equivalentCOCHLEAR NUCLEUS CI632 COCHLEAR IMPLANT WITH SLIM MODIOLAR ELECTRODE Device, Implantable hearing solution2025
2025-07-21Janssen Research & Development, LLC$4,040Research paymentCash or cash equivalentAn Open-label, Multicenter, Phase 2 Follow-on Study for Second Eye Treatment of Patients Previously Treated With a Recom2025
2025-07-15Regeneron Pharmaceuticals, Inc.$14,613Research paymentCash or cash equivalentEYLEA Biological, OPHTHALMOLOGYANTI-VEGF THERAPY FOR ACUTE THYROID EYE DISEASE (ACTED STUDY)2025
2025-07-15Regeneron Pharmaceuticals, Inc.$7,731Research paymentCash or cash equivalentEYLEA Biological, OPHTHALMOLOGYANTI-VEGF THERAPY FOR ACUTE THYROID EYE DISEASE (ACTED STUDY)2025
2025-07-15Gyrus ACMI, Inc.$56Royalty or LicenseCash or cash equivalentGYRUS ACMI Device, Ear, Nose, Throat2025
2025-07-10Carl Zeiss Meditec, Inc.$14,685GrantIn-kind items and services2025
2025-07-10Carl Zeiss Meditec, Inc.$2,250GrantCash or cash equivalent2025
2025-07-07Sumitomo Pharma America, Inc.$3,981Research paymentCash or cash equivalentA PROSPECTIVE, OBSERVATIONAL STUDY IN ADULTS WITH RETINITIS PIGMENTOSA (RP)2025
2025-07-07Sumitomo Pharma America, Inc.$3,981Research paymentCash or cash equivalentA PROSPECTIVE, OBSERVATIONAL STUDY IN ADULTS WITH RETINITIS PIGMENTOSA (RP)2025
2025-07-07Sumitomo Pharma America, Inc.$3,981Research paymentCash or cash equivalentA PROSPECTIVE, OBSERVATIONAL STUDY IN ADULTS WITH RETINITIS PIGMENTOSA (RP)2025
2025-07-07Sumitomo Pharma America, Inc.$3,981Research paymentCash or cash equivalentA PROSPECTIVE, OBSERVATIONAL STUDY IN ADULTS WITH RETINITIS PIGMENTOSA (RP)2025
2025-07-07Sumitomo Pharma America, Inc.$3,981Research paymentCash or cash equivalentA PROSPECTIVE, OBSERVATIONAL STUDY IN ADULTS WITH RETINITIS PIGMENTOSA (RP)2025
2025-07-07Sumitomo Pharma America, Inc.$3,981Research paymentCash or cash equivalentA PROSPECTIVE, OBSERVATIONAL STUDY IN ADULTS WITH RETINITIS PIGMENTOSA (RP)2025
2025-07-07Sumitomo Pharma America, Inc.$3,981Research paymentCash or cash equivalentA PROSPECTIVE, OBSERVATIONAL STUDY IN ADULTS WITH RETINITIS PIGMENTOSA (RP)2025
2025-07-07Sumitomo Pharma America, Inc.$3,981Research paymentCash or cash equivalentA PROSPECTIVE, OBSERVATIONAL STUDY IN ADULTS WITH RETINITIS PIGMENTOSA (RP)2025
2025-07-07Sumitomo Pharma America, Inc.$3,692Research paymentCash or cash equivalentA PROSPECTIVE, OBSERVATIONAL STUDY IN ADULTS WITH RETINITIS PIGMENTOSA (RP)2025
2025-07-07Sumitomo Pharma America, Inc.$3,692Research paymentCash or cash equivalentA PROSPECTIVE, OBSERVATIONAL STUDY IN ADULTS WITH RETINITIS PIGMENTOSA (RP)2025
2025-07-07Sumitomo Pharma America, Inc.$3,692Research paymentCash or cash equivalentA PROSPECTIVE, OBSERVATIONAL STUDY IN ADULTS WITH RETINITIS PIGMENTOSA (RP)2025
2025-07-07Sumitomo Pharma America, Inc.$3,692Research paymentCash or cash equivalentA PROSPECTIVE, OBSERVATIONAL STUDY IN ADULTS WITH RETINITIS PIGMENTOSA (RP)2025
2025-07-07Sumitomo Pharma America, Inc.$3,692Research paymentCash or cash equivalentA PROSPECTIVE, OBSERVATIONAL STUDY IN ADULTS WITH RETINITIS PIGMENTOSA (RP)2025
2025-07-07Sumitomo Pharma America, Inc.$3,692Research paymentCash or cash equivalentA PROSPECTIVE, OBSERVATIONAL STUDY IN ADULTS WITH RETINITIS PIGMENTOSA (RP)2025
2025-07-07Sumitomo Pharma America, Inc.$3,692Research paymentCash or cash equivalentA PROSPECTIVE, OBSERVATIONAL STUDY IN ADULTS WITH RETINITIS PIGMENTOSA (RP)2025
2025-07-07Sumitomo Pharma America, Inc.$3,692Research paymentCash or cash equivalentA PROSPECTIVE, OBSERVATIONAL STUDY IN ADULTS WITH RETINITIS PIGMENTOSA (RP)2025
2025-06-30Janssen Research & Development, LLC$6,498Research paymentCash or cash equivalentAn Open-label, Multicenter, Phase 2 Follow-on Study for Second Eye Treatment of Patients Previously Treated With a Recom2025
2025-06-26KYOWA KIRIN, INC.$800Research paymentCash or cash equivalentA PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A 2025
2025-06-26KYOWA KIRIN, INC.$600Research paymentCash or cash equivalentA PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A 2025
2025-06-17Cochlear Americas$3,290Research paymentCash or cash equivalentImproving clinical efficiency with population mean mapping and modified follow-up schedule2025
2025-06-13Sumitomo Pharma America, Inc.$1,124Research paymentCash or cash equivalentA PROSPECTIVE, OBSERVATIONAL STUDY IN ADULTS WITH RETINITIS PIGMENTOSA (RP)2025
2025-06-13Sumitomo Pharma America, Inc.$1,050Research paymentCash or cash equivalentA PROSPECTIVE, OBSERVATIONAL STUDY IN ADULTS WITH RETINITIS PIGMENTOSA (RP)2025
2025-06-13Sumitomo Pharma America, Inc.$1,050Research paymentCash or cash equivalentA PROSPECTIVE, OBSERVATIONAL STUDY IN ADULTS WITH RETINITIS PIGMENTOSA (RP)2025
2025-06-12Janssen Research & Development, LLC$1,216Research paymentCash or cash equivalentAn Open-label, Multicenter, Phase 2 Follow-on Study for Second Eye Treatment of Patients Previously Treated With a Recom2025
2025-06-11Genentech, Inc.$20,000Space rental or facility fees (teaching hospital only)Cash or cash equivalent2025
2025-06-02Janssen Research & Development, LLC$25,366Research paymentCash or cash equivalentAn Open-label, Multicenter, Phase 2 Follow-on Study for Second Eye Treatment of Patients Previously Treated With a Recom2025
2025-06-02Janssen Research & Development, LLC$2,241Research paymentCash or cash equivalentAn Open-label, Multicenter, Phase 2 Follow-on Study for Second Eye Treatment of Patients Previously Treated With a Recom2025
2025-06-02Janssen Research & Development, LLC$1,549Research paymentCash or cash equivalentAn Open-label, Multicenter, Phase 2 Follow-on Study for Second Eye Treatment of Patients Previously Treated With a Recom2025
2025-05-31Janssen Research & Development, LLC$20,978Research paymentCash or cash equivalentLong-term Follow-up Gene Therapy Study for RPGR- XLRP2025
2025-05-31Janssen Research & Development, LLC$15,078Research paymentCash or cash equivalentLong-term Follow-up Gene Therapy Study for RPGR- XLRP2025
2025-05-31Janssen Research & Development, LLC$8,166Research paymentCash or cash equivalentLong-term Follow-up Gene Therapy Study for RPGR- XLRP2025
2025-05-30Sumitomo Pharma Co., Ltd.$5,854Research paymentCash or cash equivalent2025
2025-05-28Spark Therapeutics, Inc.$12,992Research paymentCash or cash equivalentLUXTURNA Biological, OCULARA POST-AUTHORIZATION, MULTICENTER, LONGITUDINAL, OBSERVATIONAL SAFETY REGISTRY STUDY FOR PATIENTS TREATED WITH VORETIGEN2025
2025-05-27Amgen Inc.$1,331Research paymentCash or cash equivalentA Phase 1/2, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study to Assess the Safety, Pharmacokinetics, an2025
2025-05-21Spark Therapeutics, Inc.$30,340Research paymentCash or cash equivalentLUXTURNA Biological, OCULARA POST-AUTHORIZATION, MULTICENTER, LONGITUDINAL, OBSERVATIONAL SAFETY REGISTRY STUDY FOR PATIENTS TREATED WITH VORETIGEN2025
2025-05-16Astellas Pharma US Inc$10,000GrantCash or cash equivalentIzervay Drug, Ophthalmology2025
2025-05-15Bausch & Lomb Americas Inc.$70,163Royalty or LicenseCash or cash equivalentVISUDYNE Drug, Ophthalmology2025
2025-05-15Stryker Corporation$3,180GrantCash or cash equivalent2025
2025-05-07Glaukos Corporation$5,977Research paymentCash or cash equivalentUK-NXL System Device, OphthalmologyAn Image Collection Study of Corneal Ulcers in Adult Participants2025
2025-05-07Spark Therapeutics, Inc.$918Research paymentCash or cash equivalentLUXTURNA Biological, OCULARA POST-AUTHORIZATION, MULTICENTER, LONGITUDINAL, OBSERVATIONAL SAFETY REGISTRY STUDY FOR PATIENTS TREATED WITH VORETIGEN2025
2025-05-07Glaukos Corporation$541Research paymentCash or cash equivalentUK-NXL System Device, OphthalmologyAn Image Collection Study of Corneal Ulcers in Adult Participants2025
2025-05-06Cochlear Americas$750Debt forgivenessCash or cash equivalentCOCHLEAR NUCLEUS CI632 COCHLEAR IMPLANT WITH SLIM MODIOLAR ELECTRODE Device, Implantable hearing solution2025
2025-05-02Janssen Research & Development, LLC$7,001Research paymentCash or cash equivalentAn Open-label, Multicenter, Phase 2 Follow-on Study for Second Eye Treatment of Patients Previously Treated With a Recom2025
2025-04-30Cochlear Americas$54,370Research paymentIn-kind items and servicesMeasures sensitive to the presence of auditory nerve peripheral processes in patients with and without DFNA9 mutations2025
2025-04-28KYOWA KIRIN, INC.$4,467Research paymentCash or cash equivalentA PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A 2025
2025-04-28KYOWA KIRIN, INC.$1,367Research paymentCash or cash equivalentA PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A 2025
2025-04-28KYOWA KIRIN, INC.$800Research paymentCash or cash equivalentA PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A 2025
2025-04-28KYOWA KIRIN, INC.$750Research paymentCash or cash equivalentA PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A 2025
2025-04-28KYOWA KIRIN, INC.$222Research paymentCash or cash equivalentA PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A 2025
2025-04-28KYOWA KIRIN, INC.$200Research paymentCash or cash equivalentA PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A 2025
2025-04-28KYOWA KIRIN, INC.$200Research paymentCash or cash equivalentA PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A 2025
2025-04-28KYOWA KIRIN, INC.$200Research paymentCash or cash equivalentA PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A 2025
2025-04-28KYOWA KIRIN, INC.$200Research paymentCash or cash equivalentA PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A 2025
2025-04-28KYOWA KIRIN, INC.$200Research paymentCash or cash equivalentA PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A 2025
2025-04-24Stryker Corporation$2,120GrantCash or cash equivalent2025
2025-04-22KARL STORZ Endoscopy-America$1,000GrantCash or cash equivalent2025
2025-04-22Cochlear Americas$170Debt forgivenessCash or cash equivalentCOCHLEAR NUCLEUS CI632 COCHLEAR IMPLANT WITH SLIM MODIOLAR ELECTRODE Device, Implantable hearing solution2025
2025-04-01iotaMotion, Inc.$3,000Space rental or facility fees (teaching hospital only)Cash or cash equivalentiotaSOFT Device, Implantable Hearing Device2025
2025-03-31Advanced Bionics, LLC$10,000GrantCash or cash equivalentHIRES ULTRA CI HIFOCUS MS ELECTRODE Device, OTOLARYNGOLOGY2025
2025-03-31KYOWA KIRIN, INC.$4,765Research paymentCash or cash equivalentA PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A 2025
2025-03-31KYOWA KIRIN, INC.$2,441Research paymentCash or cash equivalentA PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A 2025
2025-03-31KYOWA KIRIN, INC.$346Research paymentCash or cash equivalentA PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A 2025
2025-03-31KYOWA KIRIN, INC.$250Research paymentCash or cash equivalentA PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A 2025
2025-03-31KYOWA KIRIN, INC.$192Research paymentCash or cash equivalentA PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A 2025
2025-03-31KYOWA KIRIN, INC.$174Research paymentCash or cash equivalentA PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A 2025
2025-03-31KYOWA KIRIN, INC.$128Research paymentCash or cash equivalentA PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A 2025
2025-03-29Bausch & Lomb Americas Inc.$10,000GrantCash or cash equivalent2025
2025-03-28Janssen Research & Development, LLC$3,727Research paymentCash or cash equivalentAn Open-label, Multicenter, Phase 2 Follow-on Study for Second Eye Treatment of Patients Previously Treated With a Recom2025
2025-03-28KYOWA KIRIN, INC.$330Research paymentCash or cash equivalentA PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A 2025
2025-03-28KYOWA KIRIN, INC.$222Research paymentCash or cash equivalentA PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A 2025
2025-03-28KYOWA KIRIN, INC.$222Research paymentCash or cash equivalentA PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A 2025
2025-03-28KYOWA KIRIN, INC.$70Research paymentCash or cash equivalentA PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A 2025
2025-03-28KYOWA KIRIN, INC.$62Research paymentCash or cash equivalentA PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A 2025
2025-03-263NT Medical$2,000GrantCash or cash equivalentColibri Micro ENT Scope Device, ENT2025
2025-03-24Cochlear Americas$3,290Research paymentCash or cash equivalentImproving clinical efficiency with population mean mapping and modified follow-up schedule2025
2025-03-21Sumitomo Pharma America, Inc.$16,000Research paymentCash or cash equivalentA PROSPECTIVE, OBSERVATIONAL STUDY IN ADULTS WITH RETINITIS PIGMENTOSA (RP)2025
2025-03-21Sumitomo Pharma America, Inc.$1,500Research paymentCash or cash equivalentA PROSPECTIVE, OBSERVATIONAL STUDY IN ADULTS WITH RETINITIS PIGMENTOSA (RP)2025
2025-03-12Cochlear Americas$2,500Charitable ContributionCash or cash equivalentCOCHLEAR NUCLEUS CI632 COCHLEAR IMPLANT WITH SLIM MODIOLAR ELECTRODE Device, Implantable hearing solution2025
2025-03-05Cochlear Americas$26Debt forgivenessCash or cash equivalentCOCHLEAR NUCLEUS CI632 COCHLEAR IMPLANT WITH SLIM MODIOLAR ELECTRODE Device, Implantable hearing solution2025
2025-02-27Heidelberg Engineering, Inc.$3,000Space rental or facility fees (teaching hospital only)Cash or cash equivalentSpectralis Device, Ophthalmology Imaging Equipment2025
2025-02-25AERIN MEDICAL INC.$5,000Long term medical supply or device loanIn-kind items and servicesVIVAER STYLUS Device, EAR NOSE & THROAT2025
2025-02-24Janssen Research & Development, LLC$24,400Research paymentCash or cash equivalentAn Open-label, Multicenter, Phase 2 Follow-on Study for Second Eye Treatment of Patients Previously Treated With a Recom2025
2025-02-15Philips North America LLC$14,000Research paymentIn-kind items and servicesUpgrade of Ingenia 3.0T and Elition X to MR 7700 Device, Medical DeviceMEE-0000: Novel Techniques in Head and Neck Imaging2025
2025-02-14Bausch & Lomb Americas Inc.$231,618Royalty or LicenseCash or cash equivalentVISUDYNE Drug, Ophthalmology2025
2025-02-04Gyrus ACMI, Inc.$1,083Royalty or LicenseCash or cash equivalentGYRUS ACMI Device, Ear, Nose, Throat2025
2025-01-31Janssen Research & Development, LLC$28,469Research paymentCash or cash equivalentLong-term Follow-up Gene Therapy Study for RPGR- XLRP2025
2025-01-31Janssen Research & Development, LLC$14,035Research paymentCash or cash equivalentLong-term Follow-up Gene Therapy Study for RPGR- XLRP2025
2025-01-31Janssen Research & Development, LLC$6,106Research paymentCash or cash equivalentLong-term Follow-up Gene Therapy Study for RPGR- XLRP2025
2025-01-31Janssen Research & Development, LLC$4,951Research paymentCash or cash equivalentLong-term Follow-up Gene Therapy Study for RPGR- XLRP2025
2025-01-31Janssen Research & Development, LLC$2,479Research paymentCash or cash equivalentLong-term Follow-up Gene Therapy Study for RPGR- XLRP2025
2025-01-31Janssen Research & Development, LLC$1,901Research paymentCash or cash equivalentLong-term Follow-up Gene Therapy Study for RPGR- XLRP2025
2025-01-29KYOWA KIRIN, INC.$5,214Research paymentCash or cash equivalentA PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A 2025
2025-01-27KYOWA KIRIN, INC.$685Research paymentCash or cash equivalentA PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A 2025
2025-01-27KYOWA KIRIN, INC.$553Research paymentCash or cash equivalentA PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A 2025
2025-01-27KYOWA KIRIN, INC.$222Research paymentCash or cash equivalentA PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A 2025
2025-01-24KYOWA KIRIN, INC.$6,584Research paymentCash or cash equivalentA PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A 2025
2025-01-24KYOWA KIRIN, INC.$3,648Research paymentCash or cash equivalentA PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A 2025
2025-01-24KYOWA KIRIN, INC.$3,316Research paymentCash or cash equivalentA PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A 2025
2025-01-14Regeneron Pharmaceuticals, Inc.$6,568Research paymentCash or cash equivalentEYLEA Biological, OPHTHALMOLOGYANTI-VEGF THERAPY FOR ACUTE THYROID EYE DISEASE (ACTED STUDY)2025
2025-01-03Stryker Corporation$4,000GrantCash or cash equivalent2025
2025-01-03Cochlear Americas$20Debt forgivenessCash or cash equivalentCOCHLEAR NUCLEUS CI632 COCHLEAR IMPLANT WITH SLIM MODIOLAR ELECTRODE Device, Implantable hearing solution2025
2025-01-02Regeneron Pharmaceuticals, Inc.$22,330Research paymentCash or cash equivalentEYLEA Biological, OPHTHALMOLOGYANTI-VEGF THERAPY FOR ACUTE THYROID EYE DISEASE (ACTED STUDY)2025

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

Suffolk CountyBoston city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In Boston, MA, county Suffolk County, MA, state Massachusetts; placed by its city name.

MeasurePlace (city or town)
Boston, MA
County
Suffolk County, MA
State
Massachusetts
Population B01003666,442785,1217,044,056
Population, 2020 census P1675,647797,9367,029,917
Median age B0100233.333.940.0
Under 18 B0100115.1%16.0%19.4%
65 and over B0100113.0%13.3%17.9%
Households B11001283,374327,1672,785,042
Foreign born B0500227.8%29.8%18.0%
Median household income B19013$97,344$95,631$103,960
Median family income B19113$116,436$112,072$131,675
Per capita income B19301$61,698$58,636$57,897
Poverty rate B1700116.6%16.2%10.0%
Unemployment rate B230256.1%6.3%5.2%
Civilian labor force B23025402,354468,6363,911,446
Mean commute (minutes) B0801330.330.929.1
Bachelor's degree or higher B1500354.9%50.6%47.3%
Housing units B25001310,625357,2903,030,406
Owner-occupied B2500335.7%36.5%62.5%
Renters B2500364.3%63.5%37.5%
Median home value B25077$731,700$705,800$562,100
Median gross rent B25064$2,147$2,129$1,762
White, not Hispanic B0300244.1%43.6%66.6%
Black B0300219.3%17.1%6.4%
Hispanic or Latino B0300219.3%23.2%13.3%
Asian B0300210.3%9.2%7.3%
American Indian and Alaska Native B030020.1%0.1%0.1%

Economy now FRED unemployment 4.3% in Sep 2026 (4.6% a year earlier); per capita personal income $98,700 in 2025, up 27% in five years (+2.3% after inflation); Unemployment rate: 3.8% in Sep 2016 to 4.3% in Sep 2026; low 3.0%, high 17.8% the state; Source: FRED, Federal Reserve Bank of St. Louis.

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Boston, MA.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.